Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

In July, the FDA issued a warning to patients and healthcare professionals using unapproved versions of the drugs for weight ...

Compounding pharmacies, drugmakers and the FDA share concerns about fake or subpar weight loss drugs — even though regulated compounders often get lumped together with illicit sources by the ...

The FDA’s sudden shift highlights challenges regulators and the pharmaceutical industry have faced amid unprecedented demand for the blockbuster weight-loss drugs. “The credibility of the FDA ...

FDA Says Compounding Pharmacies ... Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct ...

Federal regulators shook up the booming weight loss ... drugs as Ozempic and Wegovy, all of them being GLP-1 agonists. Tirzepatide was first approved by the Food and Drug Administration (FDA ...

Just last week the agency said the years-long shortage of the blockbuster drug had come to an end. Under agency guidelines, the FDA warned at the time, compounding pharmacies would no longer be ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...

The Food and Drug Administration has updated labels for popular weight loss drugs like Ozempic and Wegovy. NFL News: ...